Targeting the lung using siRNA and antisense based oligonucleotides
Sterghios A Moschos1, Karen Spinks, Andrew E Williams
1Respiratory Research Group, Wythenshawe Hospital, School of Translational Medicine, University of Manchester, M23 9LT, UK.
Abstract:
The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.
Insights
The lung is a promising target for oligonucleotide therapeutics via inhalation. This review explores challenges in antisense and siRNA delivery, stability, and immune responses for effective lung-targeted treatments.
Area of Science:
- Pharmacology
- Molecular Biology
- Respiratory Medicine
Background:
- The lung's large surface area and accessibility via inhalation make it an attractive site for topical drug delivery.
- Oligonucleotide-based therapeutics, including antisense and small interfering RNA (siRNA), show potential for treating lung diseases.
Purpose of the Study:
- To critically review the challenges and opportunities for using antisense and siRNA therapeutics targeting the lung.
- To evaluate key factors influencing the efficacy and safety of inhaled oligonucleotide therapies.
Main Methods:
- Literature review focusing on in vivo target validation for antisense and siRNA approaches.
- Analysis of factors including delivery, distribution, stability, off-target effects, and immunogenicity.
- Discussion on the selection of optimal messenger RNA (mRNA) targets for therapeutic intervention.
Main Results:
- Inhalation offers a viable route for topical lung delivery of oligonucleotide therapeutics.
- Significant challenges remain in achieving effective delivery, distribution, and stability within lung tissues.
- Off-target effects and unwanted immune responses are critical safety considerations for these therapies.
Conclusions:
- Despite challenges, the lung presents a significant therapeutic target for oligonucleotide-based drugs.
- Further research is needed to optimize delivery systems and overcome biological barriers for successful clinical application.
- Careful target selection and mitigation of adverse effects are crucial for developing safe and effective lung oligonucleotide therapies.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

